Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.8M
-
Number of holders
-
130
-
Total 13F shares, excl. options
-
44.9M
-
Shares change
-
+117K
-
Total reported value, excl. options
-
$401M
-
Value change
-
+$808K
-
Put/Call ratio
-
2
-
Number of buys
-
56
-
Number of sells
-
-63
-
Price
-
$8.93
Significant Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q1 2025
149 filings reported holding TBPH - Theravance Biopharma, Inc. - Common Stock as of Q1 2025.
Theravance Biopharma, Inc. - Common Stock (TBPH) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.9M shares
of 49.8M outstanding shares and own 90.19% of the company stock.
Largest 10 shareholders include Madison Avenue Partners, LP (9.51M shares), Weiss Asset Management LP (7.46M shares), Newtyn Management, LLC (4.76M shares), BlackRock, Inc. (3.45M shares), Irenic Capital Management LP (2.76M shares), VANGUARD GROUP INC (2.08M shares), Park West Asset Management LLC (1.8M shares), Oasis Management Co Ltd. (1.12M shares), STATE STREET CORP (1.07M shares), and Camber Capital Management LP (1M shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.